Dateline City:
WHITEHOUSE STATION, N.J. & AMES, IA
Clinical Development, Manufacturing Expertise, and Scale Critical to Success
WHITEHOUSE STATION, N.J. & AMES, IA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
NewLink Genetics Corporation (NASDAQ:NLNK), announced today that they
have entered into an exclusive worldwide license agreement to research,
develop, manufacture, and distribute NewLinks investigational rVSV-EBOV
(Ebola) vaccine candidate.
Language:
English
Contact:
Merck Media Contacts:Pam Eisele, 267-305-3558Imraan Munshi, 215-652-0059orInvestor Contacts:NewLink GeneticsJack Henneman, 515-598-2561orMerckJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
Ticker: NLNK Exchange: NASDAQ
read more